Evidence map›Paper›PMID 29191715›Full record

ArticleClinical lymphoma, myeloma & leukemia2018

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Julie E Chang, Lakeesha L Carmichael, KyungMann Kim, Christopher Peterson, David T Yang, Anne M Traynor, Jae E Werndli, Michael S Huie, Thomas A McFarland, Michael Volk and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Mantle cell lymphoma and its management: where are we now?Experimental hematology & oncology · 2019
    Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Julie E ChangDepartment of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI. Electronic address: jc2@medicine.wisc.edu.
Lakeesha L CarmichaelDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI.
KyungMann KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI.
Christopher PetersonDepartment of Hematology/Oncology, Aspirus Cancer Center, Wausau, WI.
David T YangDepartment of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Anne M TraynorDepartment of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI.
Jae E WerndliDepartment of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI.
Michael S HuieDepartment of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI.
Thomas A McFarlandDepartment of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI.
Michael VolkDepartment of Hematology/Oncology, Saint Vincent Regional Cancer Center, Green Bay, WI.
Jules BlankDepartment of Hematology/Oncology, Saint Vincent Regional Cancer Center, Green Bay, WI.
Natalie S CallanderDepartment of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI.
Walter L LongoDepartment of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI.
Brad S KahlDivision of Medical Oncology, Washington University School of Medicine, St. Louis, MO.
University of Wisconsin Carbone Cancer Center · USUniversity of Wisconsin–Madison · USRegional Cancer Center · USAspirus Wausau Hospital · USWashington University in St. Louis · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

introductionVcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. PATIENTS AND

methodsPatients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m

conclusionsLong-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous, and durable remission can be achieved with intermediate intensity therapy. MR appears to contribute to these excellent outcomes.

Indexed as

Antineoplastic Agents, ImmunologicalFemaleHumansInduction ChemotherapyLymphoma, Mantle-CellMaleMiddle AgedProspective StudiesRemission InductionRituximabWisconsinAntineoplastic Agents, ImmunologicalRituximabAutologous stem cell transplantBortezomibHyper-CVADMIPI scoreNon-Hodgkin lymphoma

Identifiers

PMID29191715
PMCPMC5896779
OpenAlexW2766841330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.